COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。假设硼替佐米和达卡巴嗪联合治疗会提高黑素瘤和软组织肉瘤的治疗效果。具体目的是：(1)确定每周给药达卡巴嗪和硼替佐米联合的推荐剂量；(2)确定最大耐受剂量组合；(3)观察抗肿瘤活性，包括反应率(s)、反应持续时间、进展时间和治疗时间（抗肿瘤活性和治疗耐受性的衡量指标）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypotheses is that combined treatment with bortezomib and dacarbazine will result in enhanced therapeutic efficacy in melanoma and soft tissue sarcoma. The specific Aims are to : (1) Determine the recommended doses for the combination dacarbazine and bortezomib administered weekly; (2) Determine the maximum tolerated dose combination; and (3) Observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).